Development and application of a simple LC-MS method for the determination of plasma rilpivirine (TMC-278) concentrations.

作者: Masaaki Takahashi , Atsushi Hirano , Nami Okubo , Eri Kinoshita , Toshiharu Nomura

DOI: 10.2152/JMI.57.245

关键词:

摘要: Rilpivirine (TMC-278) is a second-generation non-nucleoside reverse transcriptase inhibitor that high potent against both wild-type and drug-resistant HIV-1 strains. Therefore, rilpivirine expected to treat therapy-experienced patients who failed use current drugs due the emergence of HIV mutants. The quantification in human plasma important support clinical studies determine pharmacokinetic parameters infected patients. Consequently, simple easy system concentrations has been required. In this study, we developed conventional LC-MS method quantify rilpivirine. Subsequently was validated by estimating precision accuracy for inter- intraday analysis concentration range 18-715 ng/ml. calibration curve linear range. Average ranged from 100.0 100.6%. Relative standard deviations assays were less than 3.3%. Recovery more 82.0%. These results demonstrate our provides conventional, accurate precise way plasma. This can be used routine application patients, permits management drug interactions toxicity

参考文章(23)
P Narciso, P Lorenzini, M Zaccarelli, F Forbici, R Bellagamba, C Gori, A Bertoli, C Perno, S Bonfigli, M Trotta, A Antinori, Tozzi, G Liuzzi, Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome Antiviral Therapy. ,vol. 11, pp. 553- 560 ,(2006)
Aimee Wilkin, Anton L. Pozniak, Javier Morales-Ramirez, Sergio H. Lupo, Mario Santoscoy, Beatriz Grinsztejn, Kiat Ruxrungtham, Laurence T. Rimsky, Simon Vanveggel, Katia Boven, on behalf of the TMC278-C204, Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Research and Human Retroviruses. ,vol. 28, pp. 437- 446 ,(2011) , 10.1089/AID.2011.0050
R.M. Gulick, New antiretroviral drugs Clinical Microbiology and Infection. ,vol. 9, pp. 186- 193 ,(2003) , 10.1046/J.1469-0691.2003.00570.X
Laura Else, Victoria Watson, John Tjia, Andrew Hughes, Marco Siccardi, Saye Khoo, David Back, Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. Journal of Chromatography B. ,vol. 878, pp. 1455- 1465 ,(2010) , 10.1016/J.JCHROMB.2010.03.036
Patrick Dorr, Mike Westby, Susan Dobbs, Paul Griffin, Becky Irvine, Malcolm Macartney, Julie Mori, Graham Rickett, Caroline Smith-Burchnell, Carolyn Napier, Rob Webster, Duncan Armour, David Price, Blanda Stammen, Anthony Wood, Manos Perros, Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity Antimicrobial Agents and Chemotherapy. ,vol. 49, pp. 4721- 4732 ,(2005) , 10.1128/AAC.49.11.4721-4732.2005
Stefania Notari, Chiara Tommasi, Emanuele Nicastri, Rita Bellagamba, Massimo Tempestilli, Leopoldo Paolo Pucillo, Pasquale Narciso, Paolo Ascenzi, Simultaneous determination of maraviroc and raltegravir in human plasma by HPLC-UV. Iubmb Life. ,vol. 61, pp. 470- 475 ,(2009) , 10.1002/IUB.181
Masaaki Takahashi, Masao Yoshida, Tsuyoshi Oki, Naoya Okumura, Tatsuo Suzuki, Tsuguhiro Kaneda, Conventional HPLC method used for simultaneous determination of the seven HIV protease inhibitors and nonnucleoside reverse transcription inhibitor efavirenz in human plasma. Biological & Pharmaceutical Bulletin. ,vol. 28, pp. 1286- 1290 ,(2005) , 10.1248/BPB.28.1286
N. Machouf, R. Thomas, V.K. Nguyen, B. Trottier, M.R. Boulassel, M.A. Wainberg, J.P. Routy, Effects of drug resistance on viral load in patients failing antiretroviral therapy Journal of Medical Virology. ,vol. 78, pp. 608- 613 ,(2006) , 10.1002/JMV.20582
Nicole Ngo-Giang-Huong, Gonzague Jourdain, Billy Amzal, Pensiriwan Sang-a-Gad, Rittha Lertkoonalak, Naree Eiamsirikit, Somboon Tansuphasawasdikul, Yuwadee Buranawanitchakorn, Naruepon Yutthakasemsunt, Sripetcharat Mekviwattanawong, Kenneth McIntosh, Marc Lallemant, Program for HIV Prevention and Treatment (PHPT) study group, None, Resistance Patterns Selected by Nevirapine vs. Efavirenz in HIV-Infected Patients Failing First-Line Antiretroviral Treatment: A Bayesian Analysis PLoS ONE. ,vol. 6, pp. e27427- ,(2011) , 10.1371/JOURNAL.PONE.0027427